The FOXFIRE Combined Analysis did not reach its primary endpoint of an overall survival (OS) benefit for patients treated with SIRT plus first-line chemotherapy compared to patients treated with chemotherapy alone1. However, the study has significantly enriched scientific understanding of the role of SIRT in the management of mCRC, particularly in the liver, which is the organ of greatest risk and the ultimate cause of death for the majority of these patients.2-4

Adapted from Wasan HS et al. Lancet Oncol 2017; 18: 1159-71

1. Wasan HS et al. Lancet Oncol 2017; 18: 1159-71
2. Van de Eynde M et al. Rev Rec Clin Trials 2009; 4: 56–62.
3. Kennedy A et al. Int J Radiation Oncology Biol and Phys 2006; 65: 412–25.
4. Gibbs P et al. Colorect Cancer 2014; 3(4): 345–62.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.